• Users Online: 562
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
REVIEW ARTICLE
Ahead of Print

Particulate and non-particle adjuvants in Leishmaniasis Vaccine Designs: A Review


1 Beykoz University, Vocational School, Department of Medical Services and Techniques, Beykoz, Istanbul, Turkey
2 V. Akhundov National Scientific Research Medical Prophylactic Institute, Baku, Azerbaijan
3 V. Akhundov National Scientific Research Medical Prophylactic Institute, Baku, Azerbaijan;, Azerbaijan
4 Yildiz Technical University, Faculty of Chemistry and Metallurgy, Department of Bioengineering, Esenler, Istanbul, Turkey

Correspondence Address:
Ku;bra Kelleci,
Vocational School, Department of Medical Services and Techniques, Beykoz, Istanbul, Turkey. +90 505 018 0151.
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-9062.361179

Leishmaniasis is a parasitic disease with different clinical forms caused by protozoan parasites of the genus Leishmania and transmitted by the bite of an infected female sand fly. According to the World Health Organization (WHO), it is the second most common parasitic disease after malaria. According to reports published by WHO, it is known that approximately 350 million people are at risk. The disease manifests itself in different clinical forms. In addition to asymptomatic cases, cutaneous leishmaniasis (CL), which creates large lesions on the skin, and visceral leishmaniasis (VL), which causes death if not treated, especially affecting the abdominal organs, are two important clinical forms. When the studies were examined, it was seen that a clinically used vaccine against any form of human leishmaniasis has not been developed yet. In some studies, it was stated that the lack of appropriate adjuvant was responsible for the failure to develop an effective Leishmania vaccine. We can say that strong adjuvants are needed to achieve successful vaccines. In this article, adjuvants and adjuvant candidates used in vaccine studies against leishmaniasis are discussed in detail.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Kelleci K
    -  Allahverdiyev A
    -  Bagirova M
    -  Ihlamur M
    -  Abamor E&
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed591    
    PDF Downloaded0    

Recommend this journal